DSCAM and breast carcinoma: Higher expression of DSCAM-AS1 was significantly correlated with poor survival of ER+ breast cancer patients, where both the overall survival (OS) and relapse-free survival (RFS) were shorter than patients with low expression of DSCAM-AS1 (Figure 6A-B, p<0.05).